Program Overview/Statement of Need

Recently updated guidelines for HR+/HER2- advanced or metastatic breast cancer include treatment recommendations for the use of inhibitors of CDK 4/6 and the PI3K/Akt/mTOR signal cascade. The emergence and approval of several CDK 4/6 inhibitors and everolimus, an mTOR inhibitor, warrant an assessment of new and emerging data to determine which agents should be used in specific patients with differing menopausal status and treatment outcomes goals.

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer will frame treatment decisions within the context of patient cases to facilitate care that is consistent with clinical guidelines and consensus recommendations. Guidance will also be provided to appropriately integrate PI3K/Akt/mTOR and CDK 4/6 targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and post-menopausal HR+/HER2- breast cancer patients.

Target Audience

This activity is intended for community-based medical oncologists and other clinicians involved in the care of patients with advanced or metastatic breast cancer.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider-ship of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

For information about the accreditation of this activity, please email: contact@potomacme.org.

Release Date: December 1, 2018
Expiration Date: December 1, 2019

Credit Designation

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit

To receive credit, learners must complete an online post-test and evaluation located at: www.rockpointe.com/breastcancersupplement.

Fee information

There is no fee for this educational activity.

Educational Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

• Evaluate the updated clinical guidelines for combination therapies in the treatment of HR+/HER2- advanced breast cancer patients
• Integrate clinical data regarding the use of CDK 4/6 inhibitors and mTOR inhibitors to treat HR+/HER2- advanced breast cancer, including appropriate subpopulations
• Mitigate toxicities associated with multi-drug treatment regimens to improve patient outcomes
• Recognize potential drug-drug interactions to plan effective and safe treatment regimens for each patient
Disclosure Statement

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Disclosures

Faculty Content Contributors: The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jenny C. Chang, MD, Nothing to disclose
Ruth O’Regan, MD, Consultant/Independent Contractor: Eli Lilly, Genomic Health, Novartis, Pfizer; Grant/Research Support: Eisai, Novartis, Pfizer

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Shawna Graves, PhD; Blair St. Amand; Lindsay Scott, PT, DPT, ATC; Anita Turk, MD, Nothing to disclose

Editorial assistance was provided by:

Anita Turk, MD, Clinical Instructor, Hematology and Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.